MYGN
Myriad Genetics Inc
NASDAQ: MYGN · HEALTHCARE · DIAGNOSTICS & RESEARCH
$4.11
-18.29% today
Updated 2026-05-06
Market cap
$475.05M
P/E ratio
—
P/S ratio
0.85x
EPS (TTM)
$-4.31
Dividend yield
—
52W range
$4 – $9
Volume
1.9M
Myriad Genetics Inc (MYGN) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-41.30%
Operating margin
-21.40%
ROE
-23.50%
ROA
-7.65%
Debt/equity
0.57x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $114.28M | $-38.19M | 75.81% | -39.89% | -33.42% |
| 2007 | $157.13M | $-34.96M | 80.39% | -30.37% | -22.25% |
| 2008 | $333.63M | $47.84M | 90.31% | 11.41% | 14.34% |
| 2009 | $326.53M | $84.61M | 86.75% | 38.73% | 25.91% |
| 2010 | $362.65M | $152.30M | 87.79% | 37.25% | 42.00% |
| 2011 | $402.08M | $100.71M | 88.38% | 39.24% | 25.05% |
| 2012 | $496.00M | $112.15M | 86.96% | 36.35% | 22.61% |
| 2013 | $613.16M | $147.14M | 87.02% | 37.18% | 24.00% |
| 2014 | $778.22M | $176.22M | 85.97% | 35.27% | 22.64% |
| 2015 | $723.10M | $80.20M | 79.62% | 18.56% | 11.09% |
| 2016 | $753.80M | $125.30M | 79.13% | 22.13% | 16.62% |
| 2017 | $771.40M | $21.80M | 77.81% | 6.40% | 2.83% |
| 2018 | $772.60M | $131.00M | 77.06% | 15.36% | 16.96% |
| 2019 | $851.10M | $4.60M | 76.38% | 0.89% | 0.54% |
| 2020 | $557.00M | $-223.70M | 68.01% | -34.97% | -40.16% |
| 2021 | $690.60M | $-27.20M | 71.39% | -27.58% | -3.94% |
| 2022 | $678.40M | $-112.00M | 70.22% | -20.73% | -16.51% |
| 2023 | $753.20M | $-263.30M | 68.64% | -34.17% | -34.96% |
| 2024 | $837.60M | $-127.30M | 69.89% | -14.74% | -15.20% |
| 2025 | $824.50M | $-365.90M | 69.93% | -16.90% | -44.38% |